Paper28299466
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
Kitagawa K and 9 others. Cancer Immunol Immunother, 2017. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. Papers, record 28299466. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28299466
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bifidobacterium | Major topic |
| Cancer Vaccines | Major topic |
| Immunotherapy | Major topic |
| Mouth Neoplasms | Major topic |
| WT1 Proteins | Major topic |
| Animals | |
| Female | |
| Mice | |
| Mice, Inbred C57BL | |
| Survival Rate | |
| T-Lymphocytes, Cytotoxic |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18502632 | WT1 peptide vaccine for the treatment of cancer. | Curr Opin Immunol | 2008 | https://conductscience.org/library/papers/18502632 | PubMed |
| 2 | 20582983 | WT1 peptide immunotherapy for cancer in children and young adults. | Pediatr Blood Cancer | 2010 | https://conductscience.org/library/papers/20582983 | PubMed |
| 3 | 19389880 | A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. | Blood | 2009 | https://conductscience.org/library/papers/19389880 | PubMed |
| 4 | 20071048 | Distinct Bifidobacterium strains drive different immune responses in vitro. | Int J Food Microbiol | 2010 | https://conductscience.org/library/papers/20071048 | PubMed |
| 5 | 18354418 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18354418 | PubMed |
| 6 | 21792083 | Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. | Pancreas | 2012 | https://conductscience.org/library/papers/21792083 | PubMed |
| 7 | 25904595 | Cancer vaccines. | BMJ | 2015 | https://conductscience.org/library/papers/25904595 | PubMed |
| 8 | 24657718 | Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice. | Vaccine | 2014 | https://conductscience.org/library/papers/24657718 | PubMed |
| 9 | 26541606 | Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. | Science | 2015 | https://conductscience.org/library/papers/26541606 | PubMed |
| 10 | 25914340 | Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. | Biotechnol J | 2015 | https://conductscience.org/library/papers/25914340 | PubMed |
| 11 | 19351755 | Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19351755 | PubMed |
| 12 | 25258102 | Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. | Vaccine | 2014 | https://conductscience.org/library/papers/25258102 | PubMed |
| 13 | 10942395 | Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. | Blood | 2000 | https://conductscience.org/library/papers/10942395 | PubMed |
| 14 | 20709009 | Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. | Vaccine | 2010 | https://conductscience.org/library/papers/20709009 | PubMed |
| 15 | 20170766 | Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. | Vaccine | 2010 | https://conductscience.org/library/papers/20170766 | PubMed |
| 16 | 12772509 | Enhancing immunogenicity by CpG DNA. | Curr Opin Mol Ther | 2003 | https://conductscience.org/library/papers/12772509 | PubMed |
| 17 | 23801305 | Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells. | Mucosal Immunol | 2014 | https://conductscience.org/library/papers/23801305 | PubMed |
| 18 | 16614236 | TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. | Oncologist | 2006 | https://conductscience.org/library/papers/16614236 | PubMed |
| 19 | 7949179 | WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. | Blood | 1994 | https://conductscience.org/library/papers/7949179 | PubMed |
| 20 | 18524406 | Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. | Int J Food Microbiol | 2008 | https://conductscience.org/library/papers/18524406 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41135875 | Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine. | J Adv Res | 2026 | https://conductscience.org/library/papers/41135875 | PubMed |
| 40893667 | Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/40893667 | PubMed |
| 40299687 | Anticancer Potential of Prebiotics: Targeting Estrogen Receptors and PI3K/AKT/mTOR in Breast Cancer. | Biomedicines | 2025 | https://conductscience.org/library/papers/40299687 | PubMed |
| 40296128 | The human microbiome: redefining cancer pathogenesis and therapy. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40296128 | PubMed |
| 40282924 | Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40282924 | PubMed |
| 39905323 | Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial. | BMC Cancer | 2025 | https://conductscience.org/library/papers/39905323 | PubMed |
| 39594765 | Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39594765 | PubMed |
| 38472176 | Promising dawn in tumor microenvironment therapy: engineering oral bacteria. | Int J Oral Sci | 2024 | https://conductscience.org/library/papers/38472176 | PubMed |
| 37600773 | Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. | Front Immunol | 2023 | https://conductscience.org/library/papers/37600773 | PubMed |
| 37340017 | An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model. | Sci Rep | 2023 | https://conductscience.org/library/papers/37340017 | PubMed |
| 36803483 | Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. | BMC Cancer | 2023 | https://conductscience.org/library/papers/36803483 | PubMed |
| 36324027 | Chemopreventive role of probiotics against cancer: a comprehensive mechanistic review. | Mol Biol Rep | 2023 | https://conductscience.org/library/papers/36324027 | PubMed |
| 35522104 | Bacteria in cancer therapy: A new generation of weapons. | Cancer Med | 2022 | https://conductscience.org/library/papers/35522104 | PubMed |
| 34589578 | An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/34589578 | PubMed |
| 32564632 | Microbiome as a Target for Cancer Therapy. | Integr Cancer Ther | 2020 | https://conductscience.org/library/papers/32564632 | PubMed |
| 31500086 | Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31500086 | PubMed |
| 30949803 | Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy. | Curr Microbiol | 2019 | https://conductscience.org/library/papers/30949803 | PubMed |
| 29048978 | Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. | Hum Vaccin Immunother | 2018 | https://conductscience.org/library/papers/29048978 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28299466
GET https://conductscience.org/api/papers/v1/28299466/references?page=2